Date published: 2026-6-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

Levodopa (CAS 59-92-7)

5.0(1)
Write a reviewAsk a question

See product citations (9)

Alternate Names:
L-DOPA; 3,4-Dihydroxyphenylalanine
Application:
Levodopa is an immediate precursor of dopamine and product of tyrosine hydroxylase
CAS Number:
59-92-7
Purity:
≥98%
Molecular Weight:
197.19
Molecular Formula:
C9H11NO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Levodopa, a biochemical precursor to the neurotransmitters dopamine, norepinephrine, and epinephrine, is extensively studied in the field of neuroscience. It is a compound of great interest in research related to the understanding of the dopamine pathway. In neurobiological research, levodopa is used to investigate the mechanisms of dopamine synthesis, storage, release, and reuptake in neurons. Researchers utilize it to explore the effects of dopamine depletion on motor control, behavior, and neurological functions. Studies involving levodopa also delve into the enzyme kinetics of tyrosine hydroxylase, the rate-limiting step in catecholamine biosynthesis, to gain insights into how genetic and environmental factors may influence this critical pathway. Additionally, levodopa′s role in the central nervous system is examined for insights into compensatory mechanisms that may occur in response to neurodegeneration.


Levodopa (CAS 59-92-7) References

  1. Levodopa acts centrally to induce an antinociceptive action against colonic distension through activation of D2 dopamine receptors and the orexinergic system in the brain in conscious rats.  |  Okumura, T., et al. 2016. J Pharmacol Sci. 130: 123-7. PMID: 26883457
  2. Management of levodopa for residents with Parkinson's disease.  |  Mages, L. 2016. Nurs Older People. 28: 23-30. PMID: 27788653
  3. Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.  |  Yoosefian, M., et al. 2018. Artif Cells Nanomed Biotechnol. 46: 434-446. PMID: 29378432
  4. Levodopa inhibits the development of lens-induced myopia in chicks.  |  Thomson, K., et al. 2020. Sci Rep. 10: 13242. PMID: 32764736
  5. S-adenosylmethionine administration inhibits levodopa-induced vascular endothelial growth factor-A expression.  |  Yan, Y., et al. 2020. Aging (Albany NY). 12: 21290-21307. PMID: 33170152
  6. Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery.  |  Parhizkar, E., et al. 2021. J Chromatogr Sci. 59: 347-354. PMID: 33367562
  7. Highly Sensitive Levodopa Determination by Means of Adsorptive Stripping Voltammetry on Ruthenium Dioxide-Carbon Black-Nafion Modified Glassy Carbon Electrode.  |  Górska, A., et al. 2020. Sensors (Basel). 21: PMID: 33374345
  8. Levodopa facilitates improvements in gait kinetics at the hip, not the ankle, in individuals with Parkinson's disease.  |  Baudendistel, ST., et al. 2021. J Biomech. 121: 110366. PMID: 33873118
  9. Does levodopa aggravate Parkinson's disease?  |  Blin, J., et al. 1988. Neurology. 38: 1410-6. PMID: 3412589
  10. Interactions of a boron-containing levodopa derivative on D2 dopamine receptor and its effects in a Parkinson disease model.  |  Abad-García, A., et al. 2022. J Biol Inorg Chem. 27: 121-131. PMID: 34806120
  11. Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease.  |  Weitzel, J., et al. 2022. J Patient Saf. 18: 704-710. PMID: 35532994
  12. Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.  |  Safarpour, D., et al. 2022. Mov Disord. 37: 2153-2158. PMID: 35969014
  13. Long-duration response to levodopa.  |  Nutt, JG., et al. 1995. Neurology. 45: 1613-6. PMID: 7644063

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Levodopa, 5 g

sc-205372
5 g
$54.00

Levodopa, 25 g

sc-205372A
25 g
$171.00